Page History

I-SPY 2 (Investigation of Serial studies to Predict Your Therapeutic Response with Imaging And moLecular analysis 2) is an ongoing, multi-center trial designed to quickly identify new agents for breast cancer. Patients with high-risk disease are adaptively-randomized to either standard neoadjuvant chemotherapy (NAC) or one of several concurrent experimental arms. I-SPY 2 utilizes change in tumor volume by DCE-MRI at serial time-points during chemotherapy to adjust the randomization schema as the trial proceeds, preferentially assigning patients to receive agents showing an increasing likelihood of efficacy against their breast cancer subtype. I-SPY 2 opened in March 2010 at 20 clinical sites and is ongoing.

This collection includes DCE MRI data (original acquired images and derived parametric maps) for I-SPY 2 patients adaptively randomized to one of several different investigational regimens or control therapy between March 2010 and November 2016, along with histopathologic outcome data. Breast MRI data in this collection was acquired prospectively at over 22 clinical centers using a standardized image acquisition protocol. Patients underwent 4 MRI exams over treatment <<< add correct schema for ISPY2 from Natsuko >>> and over 95% of the DCE imaging data met acceptance criteria for analysis of functional tumor volume (FTV), a demonstrated quantitative imaging marker of breast cancer response to NAC. This is a comprehensive, highly curated imaging data set with histopathologic outcome that can be used to develop, test and compare imaging metrics and prediction models for breast cancer response to treatment. Original but uncurated T2_weighted MRI images are also included for most studies.

719 patients are included in this collection. In combination with 266 patients from the ACRIN-6698/ISPY2 TCIA collection <<< add link to 6698 wiki page >>> these 985 patients comprise "I-SPY2 Cohort 1", the 1st subgroup of publicly released patient data from the I-SPY 2 TRIAL. All subjects were randomized to one of six treatment arms graduated from the study by 2016, or to an associated control arm. In order to obtain the MRI data for the entire I-SPY2 Cohort 1 please download using the manifest file provided in the Data Access table below as this will include the patients from both collections. Downloading this collection alone will result in an incomplete cohort of 719 patients and any results from that patient set will not be comparable to published results from the trial.